Erytech Pharma Acquires Pherecydes

Pherecydes is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, and natural bacteria viruses. It is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Pherecydes was formed in 2006 and in based in Romainville, France.